FrancophonIA/ELRC3.0 huggingface dataset:
English: The AUC of FBAL increased with age (20% increase in age results in a 15% increase in the AUC of FBAL).
Croatian: AUC FBAL porasla je s dobi (20% veća dob imala je 15 %-tno povećanje AUC FBAL-a).
English: If contraindications exist to any of the medicinal products in the combination regimen, that medicinal product should not be used.
Croatian: • Ako postoje kontraindikacije za bilo koji od lijekova koji se primjenjuju u kombinacijskom protokolu, taj se lijek ne smije primjenjivati.
English: 1, every 3 weeks).
Croatian: 3 tjedna).
English: Body Surface Area (m
Croatian: Tjelesna površina (m2)
English: What Xeloda is and what it is used for What you need to know before you take Xeloda How to take Xeloda
Croatian: Što je Xeloda i za što se koristi Što morate znati prije nego počnete uzimati lijek Xeloda Kako uzimati lijek Xeloda
English: It is important that you take all your medicine as prescribed by your doctor.
Croatian: • Važno je da lijek uzimate na način koji Vam je propisao liječnik.
English: • medicines used to treat folic acid deficiency.
Croatian: • lijekove za liječenje nedostatka folatne kiseline.
English: Contact your doctor immediately if you are concerned about any of the side effects or if you notice any additional side effects not listed in the leaflet (see section 4 Possible side effects).
Croatian: Odmah se obratite svom liječniku ako ste zabrinuti zbog bilo koje nuspojave ili ako primijetite dodatne nuspojave koje nisu navedene u uputi (pogledajte dio 4.
English: • Chest pain: if you experience pain localised to the centre of the chest, especially if it occurs during exercise.
Croatian: • bol u prsištu: ako osjetite bol u sredini prsnog koša, osobito ako se pojavi tijekom vježbanja
English: It may harm them,
Croatian: onih koji su primali FOLFIRI).
English: ** Based on the post-marketing experience, persistent or severe palmar-plantar erythrodysaesthesia syndrome can eventually lead to loss of fingerprints (see section 4.4)
Croatian: **Na temelju iskustva nakon stavljanja lijeka u promet, perzistirajući ili težak sindrom palmarno-plantarne eritrodizestezije može naposljetku dovesti do gubitka otisaka prstiju (vidjeti dio 4.4).
English: Creatinine clearance was found to influence the systemic exposure to 5'-DFUR (35% increase in AUC when creatinine clearance decreases by 50%) and to FBAL (114% increase in AUC when creatinine clearance decreases by 50%).
Croatian: Uočeno je da klirens kreatinina utječe na sistemsku izloženost 5'-DFUR (35 %-tno povećanje AUC kad se klirens kreatinina smanji za 50%) i FBAL (114 %-tno povećanje AUC kad se klirens kreatinina smanji za 50%).
English: Brivudine must not be administered concomitantly with capecitabine.
Croatian: Brivudin Brivudin se ne smije primjenjivati istodobno s kapecitabinom.
English: Xeloda belongs to the group of medicines called "cytostatic medicines", which stop the growth of cancer cells.
Croatian: Xeloda pripada skupini lijekova pod nazivom „citostatici“, koji zaustavljaju rast stanica karcinoma.
English: The parameters of capecitabine, 5'-deoxy-5-fluorocytidine (5'-DFCR) and 5'-deoxy-5-fluorouridine (5'-DFUR) measured on days 1 and 14 were similar.
Croatian: Pokazatelji aktivnosti kapecitabina, 5'-deoksi-5-fluorocitidin (5'-DFCR) i 5'-deoksi-5-fluorouridin (5'-DFUR) izmjereni 1. i 14. dan bili su slični.
English: The Xeloda pivotal studies included females of childbearing potential and males only if they agreed to use an acceptable method of birth control to avoid pregnancy for the duration of the study and for a reasonable period thereafter.
Croatian: U pivotalna ispitivanja lijeka Xeloda žene reproduktivne dobi i muškarci uključeni su samo ako su pristali koristiti neku prihvatljivu metodu kontrole začeća kako bi izbjegli trudnoću tijekom trajanja ispitivanja i u razumnom razdoblju nakon toga.
English: Xeloda should be permanently discontinued in patients who experience a severe skin reaction during treatment.
Croatian: Primjenu lijeka Xeloda potrebno je trajno obustaviti u bolesnika koji razviju tešku kožnu reakciju tijekom liječenja.
English: Xeloda tablets should be swallowed whole with water within 30 minutes after a meal.
Croatian: Xeloda tablete moraju se progutati cijele s vodom najkasnije 30 minuta nakon obroka.
English: The following headings are used to rank the ADRs by frequency: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000).
Croatian: (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1000), vrlo rijetko (< 1/10 000).
English: Patients with renal impairment (see section 4.2, 4.4, and 5.2):
Croatian: Bolesnici s oštećenjem bubrežne funkcije (vidjeti dijelove 4.2, 4.4 i 5.2):
English: Patients with baseline neutrophil counts of <1.5 x 109/L and/or thrombocyte counts of <100 x 109/L should not be treated with capecitabine.
Croatian: Bolesnike s početnim brojem neutrofila <1,5 x 109/l i/ili brojem trombocita <100 x 109/l ne bi trebalo liječiti kapecitabinom.
English: In combination with other medicines the usual dose for adults may be less than 1250 mg/m2 of body surface area, and you may need to take the tablets over a different time period (e.g. every day, with no rest period).
Croatian: U kombinaciji s drugim lijekovima uobičajena doza za odrasle može biti manja od 1250 mg/m2 tjelesne površine i moguće je da ćete uzimati tablete u različitom vremenskom razdoblju (npr. svaki dan, bez prekida).
English: • if you have severely low levels of white cells or platelets in the blood (leucopenia, neutropenia or thrombocytopenia),
Croatian: • ako imate jako niske razine bijelih krvnih stanica ili krvnih pločica (leukopeniju, neutropeniju ili trombocitopeniju),
English: Xeloda contains anhydrous lactose
Croatian: Xeloda sadrži bezvodnu laktozu
English: Emil-Barell-Str. 1
Croatian: Emil-Barell-Strasse 1
English: Elderly: Based on the population pharmacokinetic analysis, which included patients with a wide range of ages (27 to 86 years) and included 234 (46%) patients greater or equal to 65, age has no influence on the pharmacokinetics of 5'-DFUR and 5-FU.
Croatian: Starije osobe: Na temelju rezultata populacijske farmakokinetske analize, koja je uključivala bolesnike širokoga dobnog raspona (od 27 do 86 godina) te 234 (46%) bolesnika od 65 godina ili starijih, ustanovljeno je da dob nema utjecaja na farmakokinetiku 5'-DFUR i 5-FU.
English: Not applicable *According to the National Cancer Institute of Canada Clinical Trial Group (NCIC CTG) Common Toxicity Criteria (version 1) or the Common Terminology Criteria for Adverse Events (CTCAE) of the Cancer Therapy Evaluation Program, US National Cancer Institute, version 4.0.
Croatian: (National Cancer Institute of Canada Clinical Trial Group - NCIC CTG), verzija 1 ili uobičajenom nazivlju kriterija za štetne događaje prema programu evaluacije terapije karcinoma Američkog nacionalnog instituta za rak, (Common Terminology Criteria for Adverse Events (CTCAE) of the Cancer Therapy Evaluation Program, US National Cancer Institute), verzija 4.0.
English: Capecitabine can induce the occurrence of diarrhoea, which has been observed in up to 50% of patients.
Croatian: Kapecitabin može inducirati pojavu proljeva, što je uočeno u najviše 50% bolesnika.
English: What you need to know before you take Xeloda
Croatian: Što morate znati prije nego počnete uzimati lijek Xeloda
English: It is therefore possible that Xeloda could affect your ability to drive a car or operate machines.
Croatian: Xeloda utječe na sposobnost upravljanja vozilima i strojevima.
English: Capecitabine dose reduction decreases systemic exposure to 5-FU more than doseproportionally, due to non-linear pharmacokinetics for the active metabolite.
Croatian: Smanjenje doze kapecitabina smanjuje sistemnu izloženost 5-FU-u više nego proporcionalno dozi, zbog nelinearne farmakokinetike aktivnoga metabolita.
English: There is no data on Xeloda and impact on fertility.
Croatian: Nema podataka o utjecaju lijeka Xeloda na plodnost.
English: The enhanced toxicity may be relevant when switching from 5- FU/LV to a capecitabine regimen.
Croatian: Povećana toksičnost može biti važna pri prelasku s 5-FU/LV na protokole koji sadrže kapecitabin.
English: Recommended posology (see section 5.1):
Croatian: Preporučeno doziranje (vidjeti dio 5.1):
English: • if you have imbalances of ions in your blood (electrolyte imbalances, seen in tests)
Croatian: • ako imate poremećaj razine iona u krvi (poremećaj ravnoteže elektrolita, vidi se iz nalaza pretraga)
English: 5-Fluorouracil: intravenous bolus injection immediately after leucovorin
Croatian: intravenska bolus injekcija odmah nakon leukovorina
English: • problems with liver function (seen in blood tests) and increased blood bilirubin (excreted by the liver)
Croatian: • problemi s radom jetre (vide se iz nalaza krvnih pretraga) i povišeni bilirubin (tvar koju luči jetra) u krvi
English: *EPP=eligible patient population; **ITT=intent-to-treat population
Croatian: *EPP = populacija pogodnih bolesnika; **ITT = populacija bolesnika predviđenih za liječenje
English: Dehydration may cause acute renal failure, especially in patients with pre-existing compromised renal function or when capecitabine is given concomitantly with known nephrotoxicmedicinal products.
Croatian: Dehidracija može izazvati akutno zatajenje bubrega, osobito u bolesnika s otprije kompromitiranom bubrežnom funkcijom ili kada se kapecitabin daje istodobno s poznatim nefrotoksičnim lijekovima.
English: The European Medicines Agency has waived the obligation to conduct studies with Xeloda in all subsets of the paediatric population in adenocarcinoma of the colon and rectum, gastric adenocarcinoma and breast carcinoma (see section 4.2 for information on paediatric use).
Croatian: Europska agencija za lijekove izuzela je obvezu provođenja ispitivanja lijeka Xeloda u svim podskupinama pedijatrijske populacije za indikacije adenokarcinoma kolona i rektuma, adenokarcinoma želuca i karcinoma dojke (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
English: Children and adolescents Xeloda is not indicated in children and adolescents.
Croatian: Xeloda nije namijenjena za primjenu u djece i adolescenata.
English: If the calculated creatinine clearance decreases during treatment to a value below 30 ml/min, Xeloda should be discontinued.
Croatian: Ako se izračunati klirens kreatinina smanji tijekom liječenja ispod 30 ml/min liječenje lijekom Xeloda treba prekinuti.
English: • if you know that you do not have any activity of the enzyme dihydropyrimidine dehydrogenase (DPD)
Croatian: • ako znate da nemate nikakvu aktivnost enzima dihidropirimidin dehidrogenaze (DPD)
English: Severe skin reactions: Xeloda can induce severe skin reactions such as Stevens-Johnson syndrome and Toxic Epidermal Necrolysis.
Croatian: Xeloda može potaknuti razvoj teških kožnih reakcija poput Stevens-Johnsonova sindroma i toksične epidermalne nekrolize.
English: The pharmacokinetics of capecitabine have been evaluated over a dose range of 502-3514 mg/m2/day.
Croatian: Farmakokinetika kapecitabina procjenjivana je u rasponu dnevne doze od 502 do 3514 mg/m2.
English: A person whose body weight is 80 kg and height is 1.80 m has a body surface area of 2.00 m2 and should take 5 tablets of 500 mg two times daily.
Croatian: Osoba čija tjelesna težina iznosi 80 kg, a visina 1,80 m, ima tjelesnu površinu od 2,00 m2 te mora uzimati 5 tableta od 500 mg dvaput dnevno.
English: Some of these side effects are more common when capecitabine is used with other medicines for the treatment of cancer.
Croatian: Neke od ovih nuspojava javljaju se češće kad se kapecitabin primjenjuje zajedno s drugim lijekovima za liječenje raka.
English: *PPP=per-protocol population; **ITT=intent-to-treat population
Croatian: *PPP = populacija po protokolu; **ITT = populacija bolesnika predviđenih za liječenje
English: Table 9 Key efficacy results for the non-inferiority analysis of Study NO16967
Croatian: Tablica 9 Ključni rezultati djelotvornosti iz analize neinferiornosti u ispitivanju NO 16967 PRIMARNA ANALIZA
English: Toxic leukoencephalopathy (very rare)
Croatian: periferna neuropatija toksična leukoencefalopatija (vrlo rijetko)
English: • if you are being treated now or have been treated in the last 4 weeks with brivudine as part of herpes zoster (chickenpox or shingles) therapy.
Croatian: • ako se liječite ili ste se u zadnja 4 tjedna liječili brivudinom u sklopu liječenja herpes zostera
English: • if you have diabetes
Croatian: • ako imate šećernu bolest
English: Do not use this medicine after the expiry date which is stated on the outer carton and blister after EXP.
Croatian: Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i blisteru iza oznake „Rok valjanosti“ ili „EXP“.
English: UAB “RoБългария Рош България ЕООД Тел: +359 2 818 44 44
Croatian: Рош България ЕООД Тел: +359 2 818 44 44
English: There is some evidence that dexpanthenol is effective for hand-foot syndrome prophylaxis in patients treated with Xeloda.
Croatian: Postoje dokazi o tome da je dekspantenol djelotvoran za profilaksu sindroma šaka-stopalo u bolesnika liječenih lijekom Xeloda.
English: If you forget to take Xeloda
Croatian: Ako ste zaboravili uzeti lijek Xeloda
English: Capecitabine and its metabolites are predominantly excreted in urine; 95.5% of administered capecitabine dose is recovered in urine.
Croatian: Kapecitabin i njegovi metaboliti većinom se izlučuju urinom; 95,5%
English: Xeloda contains capecitabine, which itself is not a cytostatic medicine.
Croatian: Xeloda sadrži kapecitabin, koji sam po sebi nije citostatik.
English: Coumarin-derivative anticoagulants: altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon.
Croatian: Kumarinski antikoagulansi Promijenjeni koagulacijski parametri i/ili krvarenje zabilježeni su u bolesnika koji su kapecitabin uzimali istodobno s kumarinskim antikoagulansima, kao što su varfarin i fenprokumon.
English: Confusional state, Panic attack, Depressed mood, Libido decreased
Croatian: • stanje smetenosti, napadi panike, depresivno raspoloženje, smanjen libido
English: • if you know that you have a partial deficiency in the activity of the enzyme dihydropyrimidine dehydrogenase (DPD)
Croatian: • ako znate da imate djelomičan nedostatak aktivnosti enzima dihidropirimidin dehidrogenaze (DPD)
English: Hypotension, Hot flush, Peripheral coldness
Croatian: hipotenzija, navale vrućine, periferna hladnoća
English: This leaflet was last revised in <{MM/YYYY}><{month YYYY}>.
Croatian: Ova uputa je zadnji puta revidirana u {MM/GGGG} Ostali izvori informacija
English: If no toxicity is observed in patients ≥60 years of age treated with a reduced capecitabine starting dose in combination with docetaxel, the dose of capecitabine may be cautiously escalated to 1250 mg/m2 twice daily.
Croatian: Ako se u tih bolesnika ne uoče znakovi toksičnosti pri primjeni smanjene početne doze kapecitabina u kombinaciji s docetakselom, doza kapecitabina može se oprezno povećavati do 1250 mg/m2 dvaput dnevno.
English: • Stomatitis: if you have pain, redness, swelling or sores in your mouth and/or throat.
Croatian: • stomatitis: osjećate li bol, crvenilo, oteklinu ili imate rane u ustima i/ili grlu.
English: Combination therapy in adjuvant colon cancer
Croatian: Kombinirana terapija u adjuvantnom liječenju karcinoma kolona
English: In the study published by Skof et al, patients were randomised to receive either FOLFIRI or XELIRI .
Croatian: U ispitivanju koje su objavili Skof i sur., bolesnici su randomizirani da primaju protokole FOLFIRI ili XELIRI.
English: Xeloda should only be prescribed by a qualified physician experienced in the utilisation of antineoplastic medicinal products.
Croatian: Lijek Xeloda može propisati samo liječnik specijalist s iskustvom u primjeni antineoplastičnih lijekova.
English: During pregnancy and lactation,
Croatian: • Trudnoća i dojenje,
English: Capecitabine is first metabolised by hepatic carboxylesterase to 5'-DFCR, which is then converted to 5'-DFUR by cytidine deaminase, principally located in the liver and tumour tissues.
Croatian: Biotransformacija Kapecitabin se najprije metabolizira jetrenom karboksilesterazom u 5'-DFCR, koji se pomoću citidin deaminaze pretvara u 5'-DFUR koji se uglavnom nalazi u jetri i tumorskim tkivima.
English: Hazard ratio 95% CI
Croatian: Omjer hazarda 95% CI P-vrijednost
English: Phase I studies evaluating the effect of capecitabine on the pharmacokinetics of either docetaxel or paclitaxel and vice versa showed no effect by capecitabine on the pharmacokinetics of docetaxel or paclitaxel (Cmax and AUC) and no effect by docetaxel or paclitaxel on the pharmacokinetics of 5'DFUR.
Croatian: Klinička ispitivanja faze I u kojima se ocjenjivao učinak kapecitabina na farmakokinetiku docetaksela ili paklitaksela i obratno nisu pokazala nikakav učinak kapecitabina na farmakokinetiku docetaksela ili paklitaksela (Cmax i AUC) niti je utvrđen učinak docetaksela ili paklitaksela na farmakokinetiku 5'-DFUR.
English: These dose adjustment recommendations for renal impairment apply both to monotherapy and combination use (see also section “Elderly” below).
Croatian: Preporuke o prilagodbi doziranja u slučaju oštećenja bubrežne funkcije odnose se i na monoterapiju i na kombiniranu primjenu (vidjeti ispod dio „Starije osobe“).
English: -2nd appearance -3rd appearance -4th appearance
Croatian: -2. pojavljivanje -3. pojavljivanje -4. pojavljivanje
English: Table 6 Treatment regimens in study NO16966 (mCRC) Treatment
Croatian: Protokoli liječenja su prikazani u Tablici 6. Tablica 6 Protokoli liječenja u ispitivanju NO16966 (mCRC)
English: Patients with moderately impaired renal function show an increased rate of dose reduction (44%) vs. 33% and 32% in patients with no or mild renal impairment and an increase in early withdrawals from treatment (21% withdrawals during the first two cycles) vs. 5% and 8% in patients with no or mild renal impairment.
Croatian: Bolesnici s umjerenim oštećenjem bubrežne funkcije imali su povećanu stopu smanjenja doze (44%) nasuprot 33% i 32% kod bolesnika bez oštećenja ili s blagim oštećenjem bubrežne funkcije i češće su prekidali terapiju (21% tijekom prva dva ciklusa) nasuprot 5% i 8% kod bolesnika bez oštećenja ili s blagim oštećenjem bubrežne funkcije.
English: In addition to the ADRs described in tables 4 and 5, the following ADRs with an incidence of less than 0.1% were associated with the use of capecitabine monotherapy based on a pooled analysis from clinical safety data from 7 clinical trials including 949 patients (2 phase III and 5 phase II clinical trials in metastatic colorectal cancer and metastatic breast cancer): cardiomyopathy, cardiac failure, sudden death, and ventricular extrasystoles.
Croatian: Kardiotoksičnost (vidjeti dio 4.4) Uz nuspojave opisane u tablicama 4 i 5, sljedeće nuspojave s incidencijom manjom od 0,1% su bile povezane s uporabom kapecitabina kao monoterapije, temeljeno na analizi združenih podataka o kliničkoj sigurnosti primjene iz 7 kliničkih ispitivanja na 949 bolesnika (2 faze III i 5 faza II kliničkih ispitivanja u bolesnika s metastatskim kolorektalnim karcinomom i metastatskim karcinomom dojke): kardiomiopatija, zatajenje srca, iznenadna smrt i ventrikularne ekstrasistole.
English: Xeloda is used in the treatment of colon, rectal, gastric, or breast cancers.
Croatian: Xeloda se koristi za liječenje karcinoma kolona, rektuma, želuca ili dojke.
English: If you have an unrecognised DPD deficiency and take Xeloda, you are at an increased risk of acute early-onset of severe forms of the side effects listed under section 4 Possible side effects.
Croatian: Ako ne znate da imate nedostatak DPD-a, a uzimate lijek Xeloda, imate povećan rizik od akutnog ranog nastupa teških oblika nuspojava navedenih u dijelu 4. Moguće nuspojave.
English: There is no relevant use of capecitabine in the paediatric population in the indications colon, colorectal, gastric and breast cancer.
Croatian: Nema relevantne primjene kapecitabina u pedijatrijskoj populaciji u indikaciji karcinoma kolona, kolorektalnog karcinoma, karcinoma želuca i karcinoma dojke.
English: In the absence of safety and efficacy data in patients with hepatic impairment, Capecitabine use should be carefully monitored in patients with mild to moderate liver dysfunction, regardless of the presence or absence of liver metastasis.
Croatian: Budući da nema podataka o sigurnosti i djelotvornosti primjene lijeka u bolesnika s oštećenjem jetrene funkcije, primjenu kapecitabina treba pomno nadzirati u bolesnika s blago do umjereno narušenom jetrenom funkcijom, bez obzira na to ima li bolesnik ili ne jetrene metastaze.
English: Discontinue permanently or If physician deems it to be in the patient's best interest to continue, interrupt until resolved to grade 0-1
Croatian: Trajno obustaviti ili ako liječnik smatra da je nastavak liječenja u interesu bolesnika,
English: INFORMATION IN BRAILLE xeloda 150 mg
Croatian: 16. PODACI NA BRAILLEOVOM PISMU xeloda 150 mg
English: If you are a woman who could become pregnant you should use effective contraception during treatment with XELODA and for 6 months after the last dose.
Croatian: Ako ste žena koja može zatrudnjeti, morate koristiti učinkovitu metodu kontracepcije tijekom liječenja lijekom Xeloda i još 6 mjeseci nakon posljednje doze.
English: XELOX showed a trend towards superior OS with a HR of 0.87 (95% CI=[0.72; 1.05]; p=0.1486) which translates into a 13% reduction in risk of death.
Croatian: XELOX je pokazao trend prema poboljšanju ukupnog preživljenja uz omjer hazarda od 0,87 (95% CI=[0,72; 1,05]; p=0,1486), što znači 13 %-tno smanjenje rizika od smrti.
English: In human cancer xenograft models capecitabine demonstrated a synergistic effect in combination with docetaxel, which may be related to the upregulation of thymidine phosphorylase by docetaxel.
Croatian: Na ksenograftskim modelima humanog karcinoma kapecitabin je pokazao sinergističko djelovanje u kombinaciji s docetakselom, što se može dovesti u vezu s povećanjem aktivnosti timidin fosforilaze uzrokovane docetakselom.
English: Patients with hepatic impairment due to liver metastases: According to a pharmacokinetic study in cancer patients with mild to moderate liver impairment due to liver metastases, the bioavailability of capecitabine and exposure to 5-FU may increase compared to patients with no liver impairment.
Croatian: Bolesnici s oštećenjem jetrene funkcije zbog jetrenih metastaza: Prema ispitivanjima farmakokinetike u bolesnika s karcinomom koji su imali blago do umjereno narušenu funkciju jetre zbog jetrenih metastaza, bioraspoloživost kapecitabina i izloženost 5-FU mogu biti veći u usporedbi s bolesnicima koji nemaju narušenu funkciju jetre.
English: ADRs are added to the appropriate frequency grouping (Very common or Common) according to the highest incidence seen in any of the major clinical trials and are only added when they were seen in addition to those seen with capecitabine monotherapy or seen at a higher frequency grouping compared to capecitabine monotherapy (see table 4).
Croatian: Nuspojave su svrstane u odgovarajuće kategorije ukupne učestalosti (vrlo često ili često) prema najvećoj incidenciji primijećenoj u bilo kojem od glavnih ispitivanja i navode se samo ako su dodatno primijećene uz one već zabilježene kod monoterapije kapecitabinom ili ako je njihova učestalost veća u usporedbi s monoterapijom kapecitabinom (vidjeti
English: Interrupt until resolved to grade 0-1
Croatian: prekinuti dok se ne svede na stupanj
English: INFORMATION IN BRAILLE xeloda 500 mg
Croatian: 16. PODACI NA BRAILLEOVOM PISMU xeloda 500 mg
English: In case of exposure of either patient or caregiver to crushed or cut Xeloda tablets adverse drug reactions could occur (see Section 4.8).
Croatian: U slučaju izlaganja bolesnika ili njegovatelja zdrobljenim ili prelomljenim Xeloda tabletama mogu se javiti nuspojave (vidjeti dio 4.8).
English: • if you have calcium imbalances (seen in blood tests)
Croatian: • ako imate poremećaj razine kalcija (vidi se iz nalaza krvnih pretraga)